Sensorion SA
0.23
EUR
-0.01
(-4.05%)
ISIN
FR0012596468
Return %
Stock
S&P 500
1Y
-27.18
14.20
3Y
-69.18
81.12
5Y
-88.81
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Frédéric Chéreau
- Full Time Employees
- 63
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 375, rue du Professeur Joseph Blayac Montpellier OC France 34080
- IPO Date
- Apr 21, 2015
- Website
- sensorion.com
- Similar Companies
- Business
- Sensorion SA (ALSEN.PA) is a clinical-stage biotechnology company that develops novel therapies to restore, treat, and prevent hearing loss disorders associated with inner ear diseases; its pipeline rests on three pillars including gene therapies for hereditary monogenic deafness, small molecule otoprotectants, and biomarker identification programs. Founded in 2009 as a spin-off from INSERM research in Montpellier and headquartered at 375 Rue du Professeur Joseph Blayac, 34080 Montpellier, France, the company operates primarily in Europe with global clinical trial sites and focuses on unmet needs in cochlear and vestibular pathologies targeting pediatric and adult patients. Core products and programs encompass SENS-501 (OTOF-GT), a dual-AAV gene therapy in Phase 1/2 (Audiogene trial) for otoferlin deficiency-mediated congenital hearing loss with first cohort enrollment completed in December 2024 and Data Monitoring Committee review planned by end of H2 2025; GJB2-GT, an AAV-based gene therapy in preclinical CTA/IND-enabling activities for GJB2 mutation-related hearing loss across congenital, pediatric progressive, and early presbycusis indications; SENS-401 (Arazasetron), an oral small molecule with Orphan Drug Designation that completed Phase 2b in Sudden Sensorineural Hearing Loss (SSNHL) in 2022 showing significant recovery in profound cases, Phase 2a in cochlear implantation hearing preservation in 2024 meeting primary endpoint with 100% perilymph detection and superior preservation versus control per Skarzynski index, and ongoing Phase 2a (NOTOXIS) in Cisplatin-Induced Ototoxicity with topline data expected end of H2 2025 and preliminary trends of otoprotection beyond 300 mg/m2 cisplatin doses; these efforts leverage an in-house R&D platform for inner ear pathophysiology, expanded CMC capabilities for AAV production, and the OTOCONEX natural history study for patient identification. Recent developments include extension of its strategic gene therapy collaboration with Institut Pasteur through 2029 announced in January 2024; €50.5 million equity financing in February 2024 from investors including Redmile Group, Invus, Sofinnova Partners, and Aquilo Capital followed by €15 million in April 2024 extending cash runway to Q1 2026; appointment of Dr. Federico Mingozzi to the Board in January 2024 for gene therapy expertise and Laurene Danon as CFO in June 2024; first patient dosed in Audiogene trial in Q3 2024 with positive initial safety data and second/third patients added by December 2024; Phase 2a SENS-401 cochlear results presented at World Congress of Audiology in September 2024 confirming hearing preservation benefits in partnership with Cochlear Limited; positive Data Safety Monitoring Board recommendation for NOTOXIS in July 2024; and GJB2-GT proof-of-concept data presented at ESGCT in October 2024.